Guidelines for clinical treatment of early course schizophrenia
- PMID: 16879798
- DOI: 10.1007/s11920-006-0070-7
Guidelines for clinical treatment of early course schizophrenia
Abstract
Several practice guidelines have been developed for the management of schizophrenia based on the current evidence base, but only a few have focused on the early course of this illness. In this article, we review the current literature on the approaches to management of early schizophrenia (ie, the prodromal, psychotic, and recovery phases of this illness). The efficacy of psychosocial and antipsychotic agents in the prodromal phase is an area of active research. Atypical antipsychotics are the mainstay of treatment for stabilization of the acute psychotic phase. Effective approaches in the recovery phase include combining medications with individual and family interventions, supported employment, assertive community treatment, cognitive remediation, and social skills training. Although evidence-based interventions have generated new optimism among those with the illness, more efforts are needed to increase access to care in community settings.
Similar articles
-
Evidence-based treatment for schizophrenia.Psychiatr Clin North Am. 2003 Dec;26(4):939-54. doi: 10.1016/s0193-953x(03)00070-4. Psychiatr Clin North Am. 2003. PMID: 14711129 Review.
-
Cognitive remediation in the early course of schizophrenia: a critical review.Curr Pharm Des. 2012;18(4):534-41. doi: 10.2174/138161212799316091. Curr Pharm Des. 2012. PMID: 22239585 Review.
-
Treatment of the first episode of schizophrenia: an update on pharmacologic and psychological interventions.Curr Psychiatry Rep. 2008 Jun;10(3):202-9. doi: 10.1007/s11920-008-0034-1. Curr Psychiatry Rep. 2008. PMID: 18652787 Review.
-
[Update on current care guidelines: schizophrenia].Duodecim. 2013;129(8):846-7. Duodecim. 2013. PMID: 23720952 Finnish.
-
Schizophrenia.Lancet. 2004 Jun 19;363(9426):2063-72. doi: 10.1016/S0140-6736(04)16458-1. Lancet. 2004. PMID: 15207959 Review.
Cited by
-
Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics.Neuropsychiatr Dis Treat. 2016 Jan 11;12:99-108. doi: 10.2147/NDT.S96214. eCollection 2016. Neuropsychiatr Dis Treat. 2016. PMID: 26811682 Free PMC article.
-
Effectiveness and safety of blonanserin monotherapy for first-episode schizophrenia with and without prominent negative symptoms: A prospective study.World J Psychiatry. 2025 May 19;15(5):103701. doi: 10.5498/wjp.v15.i5.103701. eCollection 2025 May 19. World J Psychiatry. 2025. PMID: 40495846 Free PMC article.
-
Predictors of treatment discontinuation during an 18-month multi-site randomized trial of Cognitive Enhancement Therapy for early course schizophrenia.Psychiatry Res. 2023 Aug;326:115254. doi: 10.1016/j.psychres.2023.115254. Epub 2023 May 16. Psychiatry Res. 2023. PMID: 37267670 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical